Toshimitsu Fujii

Toshimitsu Fujii

Auto-generated profile, based on publicly available information

Toshimitsu Fujii

Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2024 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SAShintaro Akiyama
Shintaro Akiyama
HSHiromichi Shimizu
Hiromichi Shimizu
ATAkiko Tamura
Akiko Tamura
KYKaoru Yokoyama
Kaoru Yokoyama
TSToshiyuki Sakurai
Toshiyuki Sakurai
TFToshimitsu Fujii
Toshimitsu Fujii

17 March 2024 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SAShintaro Akiyama
Shintaro Akiyama
KYKaoru Yokoyama
Kaoru Yokoyama
SYSoichi Yagi
Soichi Yagi
Shinichiro ShinzakiShinichiro Shinzaki
Shinichiro Shinzaki
KTKozo Tsuruta
Kozo Tsuruta
TFToshimitsu Fujii
Toshimitsu Fujii

31 August 2020 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
MUMotoi Uchino
Motoi Uchino
HIHiroki Ikeuchi
Hiroki Ikeuchi
KHKEISUKE Hata
KEISUKE Hata
TMTomohiro Minagawa
Tomohiro Minagawa
YHYUKI HORIO
YUKI HORIO
MWMamoru Watanabe
Mamoru Watanabe

29 July 2021 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
KTKento Takenaka
Kento Takenaka
AKAmi Kawamoto
Ami Kawamoto
SHShuji Hibiya
Shuji Hibiya
KSKohei Suzuki
Kohei Suzuki
TFToshimitsu Fujii
Toshimitsu Fujii
KOKazuo Ohtsuka
Kazuo Ohtsuka

1 January 2014 in Digestion
Verified
Journal Article
Open access
PDF file
TFToshimitsu Fujii
Toshimitsu Fujii
MNMakoto Naganuma
Makoto Naganuma
YKYoshio Kitazume
Yoshio Kitazume
ESEiko Saito
Eiko Saito
MNMasakazu Nagahori
Masakazu Nagahori
MWMamoru Watanabe
Mamoru Watanabe
Crohn's disease (CD) is a lifelong chronic inflammatory bowel disease associated with diarrhea, abdominal pain, bloody stool and often perianal fistulae. Inflammation in CD involves the entire gastrointestinal tract, especially including the small and large bowels, causing irreversible bowel damage. Frequent imaging examinations are necessary to monitor disease activity and to evaluate response to therapeutic interventions, and, furthermore, to predict recurrence in order to provide appropriate treatment. The suitable imaging modality should be reproducible, well tolerated, safe and free of ionizing radiation. In recent years, imaging used in CD has dramatically changed. Cross-sectional imaging techniques such as computed tomography and magnetic resonance imaging (MRI) are used to investigate not only extraluminal abnormalities, but also intraluminal changes. Recently, new techniques such as MR enteroclysis, enterography, colonography and enterocolonography have been developed. These recent advances enable the use of MRI to assess bowel disorders with high sensitivity, specificity and accuracy. MRI can evaluate simultaneously the bowel surface, bowel wall, abdominal abscesses and perianal lesions, such as perianal fistulae and perianal abscesses, without the problem of overlapping bowel loops. Therefore, MRI has the potential for evaluation of the overall disease activity of CD without radiation exposure. We believe that MRI is a suitable first choice imaging modality in the assessment of CD.

30 January 2021 in Intestinal Research
Verified
Journal Article
Open access
PDF file
HSHiromichi Shimizu
Hiromichi Shimizu
TFToshimitsu Fujii
Toshimitsu Fujii
SHShuji Hibiya
Shuji Hibiya
MMMaiko Motobayashi
Maiko Motobayashi
KSKohei Suzuki
Kohei Suzuki
MWMamoru Watanabe
Mamoru Watanabe